Home Neuronal Signaling COX inhibitor Bromfenac Sodium

research use only

Bromfenac Sodium COX inhibitor

Cat.No.S4248

Bromfenac Sodium (AHR 10282R,Bromsite,Bromday,Prolensa,Xibrom) is a nonsteroidal anti-inflammatory drug (NSAID), which has anti-inflammatory activity and may block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2.
Bromfenac Sodium COX inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 356.15

Jump to

Quality Control

Batch: Purity: 99.63%
99.63

Solubility

In vitro
Batch:

DMSO : 71 mg/mL (199.35 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 71 mg/mL

Ethanol : 2 mg/mL

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 356.15 Formula

C15H11BrNO3.Na

 Storage (From the date of receipt)
CAS No. 91714-93-1 Download SDF Storage of Stock Solutions

Synonyms AHR 10282R,Bromsite,Bromday,Prolensa,Xibrom SMILES C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)[O-].[Na+]

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
COX1
COX-2
In vivo

Bromfenac (bromfenac sodium) by the oral route at pretreatment times of 10 min, 20 min and 300 min is respectively 3.7, 6.5 and 2.9 times more potent than zomepirac and 3.4, 6.6, and 44.2 times more potent than suprofen in the acetylcholine abdominal constriction assay in mice. Bromfenac when given orally is 5.8 times more potent than zomepirac in blocking the nociceptive response to bradykinin in dogs. Bromfenac is 6.1 to 32.8 times more potent than indometacin in inhibiting the formation of prostaglandin E2 and F2 alpha from microsomes of bovine seminal vesicles, rabbit uteri, and rabbit renal medullae. Bromfenac, given orally, is more potent than indometacin in suppressing acute (7.5-20 times) and chronic (3.8 times) inflammation in mice. Bromfenac (1 mg/kg, i.v.) is metabolited into an unusual conjugate, bromfenac N-glucoside, in rats bile. Bromfenac shows a rapid onset of activity (20 min) that persisted for at least 4 hours in a mouse model of pain (acetylcholine abdominal constriction). Bromfenac (0.316 mg/kg) produces significant anti-inflammatory activity up to 24 hours after dosing in a rat model of inflammation (carrageenan foot edema). Bromfenac is readily absorbed after oral administration, peak plasma levels being achieved at the earliest time tested: 20 min in the mouse and 30 min in the rat.

References
  • [4] https://pubmed.ncbi.nlm.nih.gov/11696108/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2025-09-17)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07178639 RECRUITING
Macular Oedema; Cataract Surgery; NSAID (Non-Steroidal Anti-Inflammatory Drug)
Nemocnice Kolín
 2025-08-01
NCT05107921 UNKNOWN
Familial Exudative Vitreoretinopathies
Seoul National University Hospital
 2021-11-01 PHASE2
NCT05158699 TERMINATED
Macular Edema; Cystoid Macular Edema; Retinal Disease; Cataract; Lens Diseases; Eye Diseases
Luigi Rondas
 2021-10-13 PHASE3
NCT07696104 COMPLETED
Pseudophakic Cystoid Macular Edema
Pomeranian Medical University Szczecin
 2020-10-14 PHASE4
NCT06785090 COMPLETED
Cataract; Cystoid Macular Edema After Phacoemulsification
Inas Abd
 2023-05-01 PHASE4
NCT06130384 COMPLETED
Pain; Intravitreal Injection; Pain, Acute
Wills Eye
 2021-03-01 PHASE4

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map